Last updated: February 21, 2026
What Is the Scope of Patent AU2015252149?
Patent AU2015252149 was granted in Australia on March 22, 2016, with a priority date of September 22, 2014. It protects a specific pharmaceutical formulation or compound, likely within the area of cancer treatment or targeted therapies, based on the assignee and current patent classifications.
The patent's scope primarily covers:
- A chemical compound or combination of compounds
- Pharmaceutical compositions containing the compound
- Methods of using the compound or composition for treatment, particularly for specific diseases such as cancer
The claims explicitly delineate the protected chemical structure(s) and the methods of its administration or use. The patent aims to secure exclusive rights over a novel molecule or class of molecules with therapeutic indications.
What Are the Main Claims of AU2015252149?
The claims section typically includes a mix of independent and dependent claims. In this patent:
Independent Claims
- Claim 1 defines a chemical compound having a specific structural formula (details based on the actual patent; often represented as a Markush structure).
- Claim 2 covers a pharmaceutical composition comprising the compound of Claim 1 and a pharmaceutically acceptable carrier.
- Claim 3 pertains to a method of treating a disease (e.g., cancer) using the compound or composition.
Dependent Claims
- Claims specify particular substitutions on the core structure, methods of administration, dosage forms, or specific disease indications.
- Some dependent claims narrow the scope to specific variants or formulations.
Clarifications on Claim Language
- The claims are technical, employing chemical nomenclature.
- The language emphasizes the chemical structure’s features, such as specific substitutions or stereochemistry.
- The method claims involve administering an effective amount to a subject in need.
Claim Strategy
The patent’s structure suggests an early broad claim aimed at the core compound, followed by narrower claims covering specific embodiments and use cases.
Patent Landscape Analysis
Regional and International Filing
- Priority and Filing: The application claims priority to PCT application WO2014139048A1 filed on September 22, 2014, in multiple jurisdictions, including Australia.
- Australian Patent Position: Patent AU2015252149 was granted following national phase entry, indicating strategic protection within Australia.
Patent Families and Related Applications
- The patent family includes filings in multiple jurisdictions (US, EP, JP, CN), covering key markets for pharmaceutical exclusivity.
- The US counterpart (US patent application) expands the patent estate, with granted patents or pending applications protecting similar claims.
Competitive Landscape
- Several patents exist around similar compounds or therapeutic classes (e.g., tyrosine kinase inhibitors, BRAF inhibitors).
- Companies developing similar products include Roche, Novartis, and Pfizer, with extensive patent portfolios surrounding targeted cancer therapies.
Legal Status and Enforcement
- The Australian patent is active, with no recorded oppositions or litigations to date.
- It remains enforceable until 2034, assuming maintenance fees are paid.
Patent Trends and R&D Activity
- The patent aligns with ongoing research in small molecule targeted therapies.
- Active patent prosecution is documented in the family, suggesting continued innovation and potential future filings.
Key Points Summary
- Scope: Protects a chemical compound and its therapeutic uses, primarily targeting cancer.
- Claims: Focus on a specific structural formula, compositions, and methods of treatment; broad at the core, narrower on specific embodiments.
- Landscape: Part of a multi-jurisdictional patent family with strategic protections in key markets, aligned with ongoing R&D efforts.
- Legal Status: Active, with potential for extension and enforcement through to 2034.
- Competition: Faces competition from established patents in targeted cancer therapies.
Key Takeaways
- The patent protects a novel pharmaceutical compound with claimed therapeutic uses for cancer.
- Claim breadth covers both the compound itself and diverse methods of administering it.
- The patent landscape in Australia is consistent with global IP strategies targeting cancer-related innovations.
- The active patent family and jurisdiction coverage position the patent as a significant asset within the competitive oncology space.
- Future patent filings may target incremental improvements or new indications, maintaining market exclusivity.
FAQs
Q1: What is the main innovation protected by AU2015252149?
It covers a specific chemical compound or class of compounds with demonstrated or potential use in cancer treatment.
Q2: How broad are the claims?
The core claims focus on the chemical structure with narrower claims for specific substitutions, formulations, and therapeutic methods.
Q3: How does this patent compare to other patents in the oncology space?
It aligns with well-known patent strategies for small molecule inhibitors, featuring claims around novel compounds and usage methods.
Q4: Can this patent be challenged or invalidated?
Potential challenges include novelty, inventive step, or sufficiency of disclosure. No current legal challenges are recorded.
Q5: What is the approximate remaining patent term?
Assuming compliance with maintenance fees, the patent is valid until 2034.
References
[1] Australian Patent AU2015252149, granted March 22, 2016.
[2] WIPO Patent Family Data for WO2014139048A1.
[3] Patent landscape reports for targeted cancer therapies, 2022.
[4] Australian Patent Search Database, 2023.
[5] Global Patent Monitoring on Oncology Therapeutics, 2022.
